Actively Recruiting
Application of Remimazolam Combined With Esketamine in Painless Gastroscopy and Colonoscopy in Elderly Patients
Led by Harbin Medical University · Updated on 2025-06-04
280
Participants Needed
1
Research Sites
146 weeks
Total Duration
On this page
Sponsors
H
Harbin Medical University
Lead Sponsor
F
First Affiliated Hospital of Harbin Medical University
Collaborating Sponsor
AI-Summary
What this Trial Is About
The objective of this clinical trial is to assess the feasibility of the remimazolam combined with esketamine OFA (opioid-free anesthesia) protocol for painless gastroscopy and colonoscopy in elderly patients and to determine if it is non-inferior to the traditional OA (opioid-containing anesthesia) protocol. The main questions it aims to answer are: * Is the remimazolam combined with esketamine protocol feasible for painless gastroscopy and colonoscopy in elderly patients? * Is the OFA protocol superior to the OA protocol? Participants will: * During anesthesia induction, the experimental group will receive remimazolam combined with esketamine for anesthesia, while the control group will receive remimazolam combined with remifentanil. * Record respiratory and circulatory indicators and adverse reaction times.
CONDITIONS
Official Title
Application of Remimazolam Combined With Esketamine in Painless Gastroscopy and Colonoscopy in Elderly Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients undergoing painless gastroenteroscopy in outpatient clinics
- Aged 65 years and above
- American Society of Anesthesiologists (ASA) grades I - III
You will not qualify if you...
- Patients with abnormal liver or kidney function
- Known respiratory or endocrine diseases
- Patients with uncontrolled hypertension and NYHA classification II-III
- Taking monoamine oxidase inhibitors, sedatives, analgesics, hypnotics, antipsychotics, antiemetics, or antidepressants
- Addiction to tobacco and alcohol
- Patients allergic to the investigational drug
- Expected difficult airway
- Body mass index (BMI) >35 kg/m²
- Have participated in other clinical trials within the past three months
- Patients with psychosocial illness or cognitive dysfunction and inability to cooperate or communicate
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China, 150001
Actively Recruiting
Research Team
L
LIU Shujie LIU
CONTACT
S
SHI Xiaoqian SHI
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here